The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
-
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02115
Boston Children's Hospital, Boston, Massachusetts, United States, 02215
Brigham and Women's Hospital, Boston, Massachusetts, United States, 02215
University of Michigan, Ann Arbor, Michigan, United States, 48109
Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Dana-Farber Cancer Institute,
Corey Cutler, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute
2026-12-31